Split-Face Double-blind Study Comparing the Onset of Action of OnabotulinumtoxinA and AbobotulinumtoxinA

Yu, Kenneth C. Y.; Nettar, Kartik; Bapna, Sumit; Boscardin, W. John; Maas, Corey S.

doi:10.1001/archfacial.2011.1142

Cited by 25 publications

(21 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6,16,19,37,43,44 Similar patterns exist for time to maximum effect and are also repeated for different target muscles. 15,16,19 …”

Section: Drug-related Factors Potentially Affecting Onset Of Activitymentioning

confidence: 66%

“…6 A second study found some degree of activity at Day 2 after injection and full onset at Day 6. 19 For the frontalis, utilizing an objective measurement method, a single study found that the median time to onset of activity with a typical dose was 12 to 18 hours, with some patients exhibiting an effect after 6 hours (Table 3). 15,16 …”

Section: The Influence Of Muscle Mass On Abo Efficacymentioning

confidence: 99%

See 1 more Smart Citation

Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration

Nestor

Ablon

Pickett

2017

Aesthetic Surgery Journal

View full text Add to dashboard Cite

Time to onset of response and duration of response are key measures of botulinum toxin efficacy that have a considerable influence on patient satisfaction with aesthetic treatment. However, there is no overall accepted definition of efficacy for aesthetic uses of botulinumtoxinA (BoNT-A). Mechanical methods of assessment do not lend themselves to clinical practice and clinicians rely instead on assessment scales such as the Frontalis Activity Measurement Standard, Frontalis Rating Scale, Wrinkle Severity Scale, and Subject Global Assessment Scale, but not all of these have been fully validated. Onset of activity is typically seen within 5 days of injection, but has also been recorded within 12 hours with abobotulinumtoxinA. Duration of effect is more variable, and is influenced by parameters such as muscle mass (including the effects of age and sex) and type of product used. Even when larger muscles are treated with higher doses of BoNT-A, the duration of effect is still shorter than that for smaller muscles. Muscle injection technique, including dilution of the toxin, the volume of solution injected, and the positioning of the injections, can also have an important influence on onset and duration of activity. Comparison of the efficacy of different forms of BoNT-A must be made with the full understanding that the dosing units are not equivalent. Range of equivalence studies for abobotulinumtoxinA (Azzalure; Ipsen Limited, Slough UK/Galderma, Lausanne CH/Dysport, Ipsen Biopharm Limited, Wrexham UK/Galderma LP, Fort Worth, TX) and onabotulinumtoxinA (Botox; Allergan, Parsippany, NJ) have been conducted, and results indicate that the number of units of abobotulinumtoxinA needs to be approximately twice as high as that of onabotulinumtoxinA to achieve the same effect. An appreciation of the potential influence of all of the parameters that influence onset and duration of activity of BoNT-A, along with a thorough understanding of the anatomy of the face and potency of doses, are essential to tailoring treatment to individual patient needs and expectations.

show abstract

“…6,16,19,37,43,44 Similar patterns exist for time to maximum effect and are also repeated for different target muscles. 15,16,19 …”

Section: Drug-related Factors Potentially Affecting Onset Of Activitymentioning

confidence: 66%

Section: The Influence Of Muscle Mass On Abo Efficacymentioning

confidence: 99%

Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration

Nestor

Ablon

Pickett

2017

Aesthetic Surgery Journal

View full text Add to dashboard Cite

show abstract

“…Despite these distinctions and anecdotal observations that these products are not interchangeable, clinical studies remain inadequate and have failed to demonstrate consistent substantive differences between neurotoxins. 6–22 Limited data suggest that incobotulinumtoxinA has a more rapid onset and longer duration, 10 whereas abobotulinumtoxinA has greater spread, 11 and onabotulinumtoxinA has greater strain reduction. 12 Importantly, all neurotoxins elicit similar positive effects on patients’ self-perception of appearance.…”

Section: Neuromodulatorsmentioning

confidence: 99%

Technical Considerations for Filler and Neuromodulator Refinements

Montes

Wilson

Chang

et al. 2016

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

show abstract

“…Botox Cosmetic undergoes a crystallization purifi cation process that yields a 900-kDa complex. The formulation of Botox Cosmetic includes fi ve (5) nanograms of botulinum toxin type A (Hall strain), NaCl, and albumin ( Yu, Nettar, Bapna, Boscardin, & Maas, 2012 ). It is vacuum dried in a 100-unit vial.…”

Section: Botox Cosmetic (Onabotulinumtoxina)mentioning

confidence: 99%

“…Dysport undergoes a chromatographic purifi cation process to yield a 500-to 900-kDa complex ( Yu et al, 2012 ). The formulation of Dysport contains 2.6 ng of botulinum toxin (Hall strain), lactose (to minimize foaming during reconstitution), and albumin; it is vacuum dried in a 300-unit vial for aesthetic use ( Pickett, O'Keeffe, & Panjwani, 2007 ).…”

Section: Dysport (Abobotulinumtoxina)mentioning

confidence: 99%

Update on Neurotoxins for Facial Rejuvenation

Brennan¹

2015

Plastic Surgical Nursing

View full text Add to dashboard Cite

The formal aesthetic introduction of botulinum toxin (i.e., neurotoxins) more than a decade ago has revolutionized the nonsurgical aesthetic market and transformed society's view of facial rejuvenation. Understanding the similarities and differences between U.S. commercially available neurotoxins, their characteristics and composition, where they are effective, their mechanism of action, and how to safely administer them will enable the aesthetic provider to successfully utilize this powerful tool and ultimately deliver optimal facial rejuvenation outcomes. An update on neurotoxins on the horizon is also provided. Please note that this article discusses neurotoxin use in treatment areas that are considered "off label" by the Food and Drug Administration.

show abstract

Split-Face Double-blind Study Comparing the Onset of Action of OnabotulinumtoxinA and AbobotulinumtoxinA

Cited by 25 publications

References 14 publications

Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration

Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration

Technical Considerations for Filler and Neuromodulator Refinements

Update on Neurotoxins for Facial Rejuvenation

Contact Info

Product

Resources

About